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We have monitored Epstein–Barr virus (EBV) IgA antibody levels of 39 nasopharyngeal carcinoma (NPC) cases for up to 15 years
before clinical onset of NPC, and assessed preclinical serologic status of another 68 cases. Our results identify a serologic window
preceding diagnosis when antibody levels are raised and sustained. This window can persist for as long as 10 years, with a mean
duration estimated to as 37728 months. Ninety-seven of these 107 NPC cases exhibited such a window. Cases that did not may
reflect individual antibody response to EBV. Serologic screening at enrollment identified those cases who had already entered the
window and became clinically manifested earlier (median¼28 months) than those who entered the window after enrollment
(median¼90 months). The former account for 19 of 21 cases diagnosed within 2 years of screening. Nasopharyngeal carcinoma risk
levels among seropositive subjects were also highest during this period. Both prediction rates and risk levels declined thereafter; cases
detected at later times were composed of increasing proportions of individuals who entered the serological window after screening.
Our findings establish EBV antibody as an early marker of NPC and suggest that repeated screening to monitor cases as they enter
this window has considerable predictive value, with practical consequences for cancer treatment.
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Nasopharyngeal carcinoma (NPC) is a major tumour in China and
elsewhere in Asia, as well as in restricted areas of Africa (Yu and
Yuan, 2002). It has a strong association with the human
herpesvirus, Epstein–Barr virus (EBV) (Raab-Traub, 2002), with
general elevation of serum EBV antibody level being an out-
standing feature of the tumour (Olds et al, 1966; Henle et al, 1970;
Henle and Henle, 1976; Ho et al, 1978a; Zeng et al, 1983; Cheng
et al, 2002; Chan et al, 2003; Fachiroh et al, 2004). EBV antibody
screening in sera of populations in high incidence areas for NPC
can be useful in predicting onset of the cancer (Yi et al, 1980; Zeng
et al, 1983; Chien et al, 2001; Ji et al, 2003a,b). This is presumed to
reflect rises in antibody levels at an early stage in cancer
development (Ho et al, 1978a; Cheng et al, 2002).
To investigate the relationship between the serologic changes
and disease progression, we have conducted a prospective study in
a high-incidence area in southern China. The study has extended
over 16 years (between 1986 and 2002) and has involved 42048
adult subjects (Ji et al, 2003b). Recruitment extended over 18
months, when each study subject was given a serologic test and a
clinical examination. Seropositive subjects identified as having
high-serum IgA antibody against EB viral capsid antigen (VCA) at
enrollment to the study were clinically and serologically followed
up on eight subsequent occasions between years 3 and 13. Some
seronegative subjects, having low IgA VCA at the time of
enrollment, were similarly examined on these occasions. Naso-
pharyngeal carcinoma cases were detected either by clinical
examination conducted during follow-up, when they symptoma-
tically presented to the out patients department (OPD) of our
hospital, or could be traced to other hospitals. We found that
cumulative NPC incidence was 20 times higher for the seropositive
subjects than seronegative subjects (Ji et al, 2003b).
We describe here changes in the preclinical serologic status
observed during the intervals between enrollment and clinical
manifestation of the tumour. The results reveal a window of about
3 years immediately preceding clinical onset, when the antibody
level was elevated and maintained at high levels. It was further
shown that virtually all cases entered this serologic window. Those
who had already entered the window at the time of enrollment
were at a more advanced stage of preclinical tumour development
than those who entered the window only after enrollment.
MATERIALS AND METHODS
Recruitment
We have conducted a clinical and serologic follow-up study of NPC
extending over a period of 16 years between December 1986 and
December 2002 in Zhongshan City in Southern China. The study
area has one of the highest incidences of the cancer in the world
(Yu and Yuan, 2002). Forty-two thousand and forty-eight normal
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sadults, 19325 male and 22723 females, aged 30–59 years (mean
age¼40.9 years), were recruited to the study with informed
consent. Recruitment extended over a period of 18 months
between December 1986 and June 1988, and the study subjects
were followed up until December 2002. A serum sample was taken
from each subject at enrollment for EBV serology, and each study
subject was given a routine clinical examination, including
examination of the nasopharynx by endoscope or mirror. Biopsy
was taken for histopathology where clinically indicated. Those with
VCA IgA titre Xcutoff value at the time of enrollment were
designated as belonging to the ‘seropositive group’ and those with
VCA IgA titre o cutoff value to the ‘seronegative group’.
Follow-up
We performed another 22279 clinical examinations on eight
subsequent occasions between year 3 and 13 of the study; 13186
examinations were performed for the seropositive group and 9093
examination for the seronegative group and serum samples taken
on each occasion for determination of EBV antibody levels.
Serology
Epstein–Barr virus-specific VCA IgA antibody level was deter-
mined by titration using an immunoenzymic assay described
previously (Yi et al, 1980). Serum samples collected during
enrollment and on subsequent occasions were tested in separate
batches. They were kept at 4
1C and used within 1 month or kept at
 201C for longer periods. The cutoff titres were set at 1:5 to 1:40
on different occasions to achieve a comparable assay specificity
of 90–95% (mean¼92%) between different test batches. The
corresponding sensitivity was 91–97%. Elevated antibody levels
were indicated when VCA IgA titre Xcutoff value.
RESULTS
Nasopharyngeal carcinoma cases detected
Table 1 shows that serologic screening conducted at enrollment
identified 3093 subjects with VCA IgA titre greater than or equal to
their respective cutoff, and are referred hitherto as ‘seropositive’.
The others had lower titre than the cutoff titre and are referred to
as ‘seronegative’. Clinical examination, including an examination
of the nasopharynx, was conducted for all the study subjects. It
detected 40 overt cases, 39 from among the seropositive subjects.
A total of 13186 follow-up examinations performed for the
seropositive subjects during routine screening resulted in detec-
tion of an additional 34 cases of NPC. Twenty-two other cases were
detected from this group not by routine screening on these
occasions but by referral to our clinic after onset of symptoms
related to underlying NPC. These symptoms included epistaxis,
nasal obstruction, hearing impairment, neck lump, headache,
facial numbness and double vision. Another 9093 examinations
were performed during routine screening for the seronegative
subjects during the same time, but the effort did not detect a single
NPC case. Seventy-five NPC cases, however, were detected from
this group but only after symptoms occurred, which prompted
patients to seek medical advice in our hospital or other hospitals in
the region.
In all, a total of 131 cases were detected from both cohorts 8
months to 15 years after enrollment, 56 from the seropositive
group and 75 from the seronegative group. The overall prediction
rate (56/131) achieved by serologic screening conducted at the
time of enrollment is similar to that reported by Chien et al (2001),
but lower than that achieved by Yi et al (1980) and Zeng et al
(1983). The cumulative incidence of the entire study population
calculated over 15 years is 21 per 10
5 person-year. The cumulative
NPC incidence of the seropositive group was 5.8 times higher than
the entire study population and that of the seronegative group, 0.5
times lower.
Diagnosis of NPC
Review of histopathology showed that 166 of a total 171 cases
detected among the study subjects were class II or III non-
keratinizing carcinoma, according to World Health Organization
(WHO) International Histological Classification of Tumors (Shan-
mugaratnam, 1991), and five cases were WHO class I keratinizing
carcinoma. However, we did not also conduct in situ hybridization
or immunohistochemistry to confirm the presence of EBV in the
tumours. Nevertheless, serum samples were taken at times of
diagnosis from 146 of these cases, and the results show that VCA
IgA titres of these patients were markedly elevated compared with
non-NPC subjects (Figure 1).
Disease staging
All patients with newly diagnosed NPC underwent clinical staging
workup, which included complete physical examination, endo-
scopy of nasopharynx, haematology and renal/liver biochemistry,
chest X-ray and computed tomography of nasopharynx and neck.
In this report, all cases of NPC were retrospectively staged
according to the 1997 American Joint Committee of Cancer
(AJCC)/International Union Against Cancer (UICC) TNM stage
classification system. Early-stage disease was defined by AJCC/
UICC stages I–II disease and advanced stage by AJCC/UICC stages
III–IV disease. Briefly, stage I disease refers to disease confined to
nasopharynx only, without cervical nodal involvement; stage II
disease involves extension to parapharyngeal space, nasal fossa or
oropharynx only, or presence of unilateral cervical nodes p6cm
above the supraclavicular fossa; stage III disease has involvement
Table 1 NPC cases detected
VCA IgA status at
enrollment
a
Seropositive Seronegative Total
Number of subjects enrolled 3093 38955 42048
NPC cases detected at
enrollment
39 1 40
Follow-up examinations
b 13186 9093 22279
Number of NPC cases detected
By routine screening
c 34 0 34
In study clinic after onset of
symptoms
d
22 51 73
In other hospital after onset
of symptoms
e
02 4 2 4
NPC case detected after
enrollment
56 75 131
Incidence (cases/10
5 person-
year)
f
120.70 12.84 20.77
Relative risk
g 5.81 0.62 1.00
NPC¼nasopharyngeal carcinoma; VCA.IgA¼viral capsid antigen IgA. Study subjects
were serologically screened and given a clinical examination at the time of enrollment.
aSerum EBV VCA IgA titre X1:5 designated seropositive, o1:5 designated
seronegative.
bPerformed on eight occasions over the subsequent 13 years either.
cBy clinical examination conducted on these occasions.
dwhen symptomatically
presented to the clinic of our hospital.
eTraced to other centers up to 15 years after
enrollment.
fCalculated over 15 years.
gCalculated as ratios of cumulative incidence of
seropositive or seronegative groups to both groups combined. All NPC cases were
WHO class II or III non-keratinizing carcinoma, except for five WHO class I cases of
keratinized carcinoma.
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sof skull base or other paranasal sinus, or presence of bilateral
cervical nodal disease p6cm above the supraclavicular fossa; stage
IV disease includes intracranial extension, cranial neuropathy or
nodal size 46cm, or involving the supraclavicular fossa.
Seventy-four of the 171 cases were detected during routine
screening, including 40 at enrollment and 34 during follow-up. The
other 97 cases were detected only after the onset of symptoms
related to underlying NPC, which occurred at different times
during follow-up (Table 2). Cases being diagnosed after onset of
symptoms referred only to those with symptoms that were clearly
related to the underlying NPC, which prompted patients to seek
medical advice leading to the diagnosis. Review of clinical records
shows that only 19.6% of the cases diagnosed after the occurrence
of symptoms had early stage disease (AJCC/UICC stages I–II),
which is similar to the percentage of early-stage disease detected
in 1629 NPC cases concurrently presenting to our OPDs between
1988 and 2003. By comparison, 67.6% of the cases detected by our
screening program had early-stage NPC. This confirms the
previous findings that the onset of most symptoms in NPC tend
to occur at a relatively late stage of the disease. Thus, participation
in the present study would not enhance the awareness of
symptoms to such an extent as to facilitate early diagnosis of the
cancer.
Occurrence of NPC after enrollment
Figure 2A shows the occurrence of the 131 NPC cases as detected at
2-yearly intervals until year 12, and then 3 years later, to year 15.
The number of cases detected from the seropositive group (solid
bars) declined over time from 20 in the first 2 years, and 12 in the
following 2 years, to two in the final 3 years. Detection of NPC
cases from the seronegative group (open bars) was delayed for 2
years initially, with only one case being detected during this time.
Detection was resumed thereafter, with 8–17 cases, as indicated,
being detected in successive periods. As a result of the distinct
occurrence of NPC among these two groups of study subjects,
prediction by serologic screening declined with time from 95%
(20/21) in the first 2 years after enrollment, and 60% (12/20) in the
following 2 years, to 12% (2/16) in the final 3 years of follow-up
(Figure 2B). Nasopharyngeal carcinoma incidence of the seropo-
sitive group (Figure 2C, solid bars) likewise declined from 323 per
10
5 person-year in the first 2 years through the subsequent
periods, to 21 per 10
5 person-year in the period 13–15 years after
enrollment. In contrast, NPC incidence of the seronegative group
(solid bars) was markedly lowered to 1.3 per 10
5 person-year in the
first 2 years after screening, rose to 10 per 10
5 person-year in the
following 2 years, and fluctuated between 10 and 21 per 10
5
person-year in the subsequent periods. Compared with the
incidence of the entire study population (hatched bars), the
relative risk of NPC in seropositive subjects declined through the
successive periods after screening from 12.9 in the first 2 years to
1.7 in years 13–15 (Figure 2D, solid bars), whereas the relative risk
of the seronegative subjects was markedly reduced to 0.05 in the
first 2 years after screening, rising to 0.4 in the following 2 years
thereafter reaching levels similar to the entire study population in
subsequent periods.
Building on previous findings (Zeng et al, 1983; Chien et al,
2001; Ji et al, 2003a; Ji et al, 2003b), the analysis shows that the
seropositive group sustained higher, but declining, levels of NPC
risk for 10 years after screening (Figure 2D), a finding attended by
a decline in prediction during this period (Figure 2B). On the other
hand, the risk sustained by seronegative individuals was markedly
lowered in the first 2 years, but rose after 4 years to a level similar
to that of both groups of study subjects combined.
Serologic follow-up of non-NPC subjects
Our study protocol had provided for a regular serologic and
clinical follow-up of all seropositive individuals. The follow-up
exercise was carried out on seven separate occasions between years
3 and 13 of the study. Seventy-eight per cent of the seropositive
subjects complied with the study protocol on the first and second
occasions, 72 and 61, 50 and 35, respectively, on the third to the
sixth occasion, declining further to 31 and 22% on the final two
occasions. Comparable number of subjects from the seronegative
group were similarly examined on these occasions. Viral capsid
antigen IgA titres in the serum samples taken on these occasions
were determined in separate batches. Cutoff titres were set at 1:20
or 1:40 to achieve a comparable specificity of 90–95% for each
sample batch tested as specificity of 92.5% achieved in the initial
screening.
As exemplified in Figure 3, antibody titres of individual non-
NPC subjects commonly fluctuated below cutoff level during
follow-up, and this is probably owing, to a large extent, to normal
assay variation. Larger fluctuation, where antibody levels rose to
and beyond cutoff titre, referred hitherto as positive seroconver-
sion, or declined below cutoff, referred hitherto as negative
seroconversion, was less common. This type of fluctuation was
0%
10%
20%
30%
40%
50%
<5 5 10 20 40 80 160 320 640
VCA IgA titer
Non-NPC, n=9093
NPC, n=146
Figure 1 Serum VCA IgA titre of NPC and non-NPC. Serum samples
were taken at times of diagnosis from 146 NPC patients (solid bar) and
another 9093 samples were taken at different times during study from non-
NPC subjects (open bar). Viral capsid antigen IgA titres of NPC patients are
significantly higher than non-NPC subjects (w
2¼2752.383, Po0.0001).
Table 2 Clinical status of NPC cases detected
AJCC/UICC stage
Detection
Number of
NPC cases I II III IV % I and II
Routine screening: 74 44 6 16 8 67.6
After onset of symptoms 97 7 12 38 40 19.6
New cases referred to our clinic 1629 173 164 578 714 20.7
AJCC/UICC¼American Joint Committee of Cancer/International Union Against
Cancer; NPC¼nasopharyngeal carcinoma. One hundred and seventy-one NPC
cases were detected from study subjects either by clinical examination during routine
screening, or when patients presented with symptoms of NPC (see Table 1 for
details). Newly diagnosed cases, usually with presence of symptoms and referred to
our out-patients clinics during the same time, served as concurrent control cases.
Percentage of stages I and II cases detected by routine screening is significantly higher
than that detected after onset of symptoms (w
2¼154.88, P¼0.000), and that of the
latter is similar as new cases referred to our clinics (w
2¼1.984, P¼0.576).
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sfurther analysed as in Table 3 by comparing the percentage of
positive and negative seroconversion observed in pairs of
consecutive samples taken at different time intervals over the
course of the study. Mean frequency of negative seroconversion of
66% for the seronegative group and 57% for the seropositive
groups were significantly higher than the corresponding values of
positive seroconversion. This suggests that the larger fluctuation in
antibody levels observed among non-NPC subjects is due to
transient rise of antibody levels, which is most likely induced by
EBV reactivation or re-infection. The results further suggest that
serologic screening conducted at enrollment may have selected a
subpopulation more prone to EBV reactivation, such that mean
percentage of seropositive conversion of seropositive group is
significantly higher than seronegative group. Mean percentage of
negative seroconversion is lower for the seropositive group than
the seronegative group, presumably because antibody response to
EBV reactivation by the seropositive group might be more
vigorous.
The preclinical EBV serologic profiles of NPC
The seropositive cases were followed up 1–7 times before
diagnosis, depending on the times of detection and compliance
in individual cases, and these include 39 individuals who later
developed NPC. Another 16 cases detected from this group were
diagnosed on or before the first follow-up exercise. One individual
(case 9) was diagnosed 114 months after enrollment, but was not
followed up due to non-compliance. Figure 4 depicts VCA IgA
serologic changes observed among the 56 NPC cases detected from
the seropositive group over the periods 8–172 months before
cancer was diagnosed. Among the 39 cases which had been
followed up at least once, the results show that 14 became
seronegative after enrollment and thereafter antibody levels
fluctuated with time, with antibody titre rising to and beyond
cutoff (solid circles) and declining below cutoff (open circles),
such as seen among non-NPC subjects (see Figure 3). In four of
these cases shown, designated ‘type III’, the antibody levels
continued to fluctuate and the individuals were seronegative at the
time of tumour diagnosis. Another six, designated ‘type II’ cases,
were seropositive at diagnosis, having undergone positive
seroconversion 1 month (case 8) to 92 months (case 42) earlier.
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Figure 2 Occurrence of NPC after screening. A total of 131 NPC cases (hatched bar) were detected at different times from 8 months to 15 years after
enrollment, 56 from seropositive group (solid bar) and 75 from seronegative group (open bar). Occurrence was analysed in successive 2 years in the first 12
years and the final 3 years in years 13–15 of the study; incidence is expressed in cases per 10
5 person-year; prediction is calculated as percentage of cases
detected from seropositive group; relative risk is calculated as ratio of incidence of seropositive or seronegative group to the corresponding value for the
total population.
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Figure 3 Fluctuating VCA IgA titres among non-NPC subjects during
follow-up. Serum samples were taken from four non-NPC subjects (HS 1
to 4) on seven occasions at the indicated times between 1987 and 1998.
Cutoff titres were set at 1:20 or 1:40 for each occasion (shaded zone).
Note that antibody titre commonly fluctuated below cutoff level, whereas
larger fluctuation, where antibody level rose to and beyond cutoff or
declined below cutoff, was less common.
EBV serologic profiles of preclinical NPC
MF Ji et al
626
British Journal of Cancer (2007) 96(4), 623–630 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sThe other four cases (cases 35, 43, 48 and 52) tested seropositive at
diagnosis and were presumed to have undergone positive
seroconversion earlier, permitting them to be designated as type
II cases. The remaining 25 cases followed up were designated ‘type
I’ cases. These individuals were seropositive at the time of
enrollment and remained so up to the time when the cancer was
diagnosed, which was 110 months for case 40. The other 17 cases,
all seropositive when diagnosed, were not followed up. Sixteen of
these were detected during or before the first follow-up exercise,
8–28 months after enrollment, and in view of the short lapse of
time, these individuals were presumed to be type I cases, having
sustained high antibody levels in the interim periods, for example
cases 56, 57 and 58. Case 9 diagnosed 114 months after enrollment
was also deemed type I, although the preclinical serologic status of
this case is uncertain.
Taken together, the results served to identify a period
immediately preceding the diagnosis of NPC, when serum EBV
antibody was raised to and sustained above cutoff titre, although
the individuals showed no apparent symptoms of cancer. Based on
the time of diagnosis of the 42 type I cases who had entered the
window before the initial screening, and 10 type II cases who
entered the window after screening, the mean duration of this
serologic window was estimated to be 37728 months. The
fluctuating antibody levels observed among the type II cases
before this window period and type III cases throughout follow-up
may reflect EBV reactivation or re-infection, such as observed
among the non-NPC subjects described earlier.
The relationship between preclinical EBV serologic
profiles and NPC tumour progression
Serum samples were taken at enrollment, and also at diagnosis,
from 51 cases detected from the seronegative group, who presented
at OPD. Forty-five of these cases were seropositive at the time of
diagnosis, evidently having entered the serologic window similar
to the type II cases described above. The other six cases were
seronegative at the time of diagnosis, like type III cases. Thus, of a
total of 107 cases that were either monitored (39 cases) or could be
assessed (68 cases) serologically, Figure 5 (left panel) shows that 97
(90%) had either entered the serologic window (42 type I cases)
before screening or would do so at some later times (55 type II
cases). Only 10 cases did not undergo a serologic change, possibly
due, in part, to the individuality of antibody responses to EBV.
Serologic screening served to locate all 42 type I cases in the
seropositive group, whereas type II defined most of the cases
detected from the seronegative group and type III cases were
randomly distributed between the two groups of study subjects.
Detection of cases extended from 8 months to 15 years, and
reflected the different stages of preclinical tumour development in
individuals when first enrolled into our study. Figure 5, right panel
shows that type I cases were at a more advanced stage of
preclinical tumour development, and were diagnosed earlier than
type II cases. Type I cases were diagnosed 8–114 months after
enrollment, with a median interval of 28 months; interquartile
intervals were 17 and 51 months, respectively. Type II cases were
detected between 13 and 177 months after enrollment, and were at
earlier stages of preclinical tumour progression than type I cases.
Their median and interquartile intervals for detection were 90
months and 60 and 134 months, respectively, which are much
longer than the corresponding values for the type I cases. Type III
cases represent a broader spectrum of tumour progression than
the other two types of cases, and were detected randomly
throughout the study. The median time of detection of these cases
was 78 months, and the interquartile intervals were between 45 and
83 months, intermediate between the corresponding values
determined for types I and II cases. The time of detection of the
three types of cases is significantly different (w
2¼39.332, df¼2,
Po0.0001).
The relationship between preclinical serologic profiles and
NPC risk status
Figure 6 compares the occurrence of NPC cases with different
preclinical serologic profiles. Serologic screening identified all 42
type I cases. These account for 19 of all 21 cases detected within the
first 2 years from both seropositive and seronegative groups. Type
II cases made up most of the cases detected from the seronegative
group. Detection of these cases was delayed for about 2 years
initially, presumably reflecting the time taken for the cases to
transit the serologic window. Detection was resumed at a relatively
constant rate thereafter, accompanied by declining detection from
among the seropositive subjects. Type III cases were few and
Table 3 Fluctuating VCA IgA titres of non-NPC subjects during follow-up
Negative seroconversion Positive seroconversion
Seropositive group Seronegative group Seropositive group Seronegative group
Years n % n % n % n %
1987–88 1705 65 0 0 1153 12
1988–90 489 70 44 89 1025 15 376 5
1990–92 374 45 23 65 1946 23 557 8
1992–93 393 47 55 67 876 18 728 5
1993–94 382 24 64 44 1000 24 750 7
1994–95 387 53 70 67 440 17 546 5
1995–98 133 68 27 59 401 14 344 6
1998–99 74 66 30 80 362 7 312 4
Mean7s.d. 3937 57717 313 66714 6050 1974 4766 773
NPC¼nasopharyngeal carcinoma; s.d.¼standard deviation; VCA IgA¼viral capsid antigen IgA. Pairs of consecutive serum samples (n) were taken at indicated intervals during
follow-up from non-NPC subjects, who were initially screened at the time of enrollment as having Xcutoff VCA IgA titre (seropositive group) or o cutoff VCA IgA titre
(seronegative group). Fluctuating antibody level was indicated, when antibody levels rose to or beyond cutoff titre (positive seroconversion) or declined below cutoff titre
(negative seroconversion). Pairs of consecutive serum samples (n) were taken at indicated intervals during follow-up from non-NPC subjects, who were initially screened at the
time of enrollment as having Xcutoff VCA IgA titre (seropositive group) or o cutoff VCA IgA titre (seronegative group). Mean percentage of negative seroconversion of either
seropositive or seronegative group is significantly higher than the corresponding values of mean percentage of positive seroconversion (w
2¼1536.33, Po0.001; w
2¼1026.66,
Po0.001); mean percentage of positive seroconversion of the positive group is significantly higher than that of the seronegative group (w
2¼299.33, Po0.001); and mean
percentage of negative seroconversion is significantly higher for the seronegative group than seropositive group (w
2¼13.82, Po0.01).
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srandomly detected, and do not contribute to respective risk status
of seropositive and seronegative groups. Thus, repeated serologic
screening to monitor type II cases as they enter the serologic
window can sustain a high prediction rate.
DISCUSSION
It is a special feature of NPC that patients commonly sustain high
levels and a broad spectrum of serum EBV antibodies (Olds et al,
1966; Henle et al, 1970; Henle and Henle, 1976; Ho et al, 1978a;
Zeng et al, 1983; Cheng et al, 2002; Chan et al, 2003; Fachiroh et al,
2004). The conditions conducive to such a state seem to be
attributed not only to the regular presence of the virus in the
tumour cells, but also to lymphoid stroma surrounding the tumour
(Ho et al, 1978b; Niedobitek et al, 1996). This serologic feature is
also observed among other NPC-like cancers, namely, lympho-
epithelioma-like carcinomas, which have the same pathology and,
like NPC, regularly harbour EBV (Begin et al, 1987; Osato and Imai
1996; Chang et al, 2002). Earlier studies suggested that a
combination of conditions required to evoke a vigorous antibody
response to EBV might be met already in NPC carcinoma in situ,
that is, at an early stage of disease shortly after a tumour has been
initiated (Sam et al, 1993; Yeung et al, 1993). This contention is
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Figure 4 Preclinical EBV serologic profiles of NPC. Fifty-six NPC cases detected from the seropositive group were followed up clinically and serologically
for various periods from the time of enrollment to times of diagnosis (month 0). Cases were separated into three categories (types I, II and III) according to
their preclinical serologic profiles: serum VCA IgA of type III cases fluctuated between Xcutoff titre (closed symbols) and o cutoff titre (open symbols)
during follow-up; that of type II cases fluctuated initially and rose to Xcutoff titre at or before diagnosis; and that of type I cases were sustained at Xcutoff
titre throughout follow-up and at diagnosis.
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sgenerally in line with anecdotal observations that elevation of EBV
antibody levels may precede NPC diagnosis by years in some
individuals (Ho et al, 1978a; Zeng et al, 1983; Yip et al, 1994).
In the present study, we monitored serologically and clinically
39 cases for different periods of up to 15 years before NPC was
diagnosed, and assessed the preclinical serologic status of another
68 cases. The study identified a serologic window marked by a
sustained elevation of EBV antibody levels. The mean duration of
this window was estimated as 37 months. Among 107 cases, we
found that 42 cases, designated type I, had already entered the
serologic window at the time of screening, 55 cases, designated
type II, would do so at different times later, and only 10 designated
type III, did not enter the window, presumably because of
the individuality of antibody response. Having already entered
the serologic window at screening, the type I cases are at more
advanced stages of preclinical tumour development and hence are
detected earlier than the type II cases, who would enter the
serologic window at later times. The type I cases became clinically
manifested after a delay of 8–114 months after screening. The
median interval for detection of type I cases was 28 months and
interquartile values were 17 and 51, respectively. Detection of the
type II cases was further delayed by 13–177 months; the median
interval was 90 months and interquartile values were 60 and 134,
respectively, which are much longer than the corresponding values
for type I cases. Type III cases were detected randomly throughout
follow-up, and the median and interquartile intervals for detection
of these cases were intermediate between the corresponding values
for type I and II cases. It was concluded from these findings that
the serologic window is a common event in the preclinical phase
of NPC development, with 97 (90%) of 107 cases either having
entered the serologic window before screening or doing so after,
thus confirming the contention that the conditions required to
evoke a vigorous antibody response to EBV are met before the
cancer becomes clinically manifested.
Serologic screening takes advantage of the above-described
features of preclinical tumour development to predict NPC. Our
effort located all 42 type I cases among the seropositive subjects,
and predicted 19 of 21 cases detected from the entire study
population within 2 years of screening. Relative NPC risk of the
seropositive subjects was also highest during this period. The
prediction rate and risk level declined at later times in proportion,
with the declining number of type I cases detected. Cases detected
from the seronegative groups were mainly made up of type II
cases, which are at earlier stages of preclinical tumour develop-
ment than type I cases. It was observed that the detection of type II
cases was delayed for about 2 years initially, presumably reflecting
the time taken for the cases to traverse the serologic window.
Thereafter, cases were detected at a relatively constant rate. These
findings show that repeated serologic screening of a target
population at regular intervals may serve as a sentinel to monitor
type II cases as they enter the serologic window, and provide a
valuable high prediction rate for these individuals.
Although cure can still be achieved in all stages of NPC in the
absence of distant metastases, the prognosis is significantly worse
in advanced-stage disease. Patients with early-stage disease have
not only improved survival rate, but also reduced toxicities of
treatment (Chan et al, 2004). Early disease symptoms are
innocuous, however, and even agreed participation in a program,
such as ours, was not accompanied by an enhanced awareness of
the cancer by the study subjects themselves, or improved early
detection. Consequently, 80% of our study cases that were
diagnosed by clinical symptoms and 79% of the concurrent
control cases of newly diagnosed NPC during the study period,
were diagnosed with advanced-stage disease. Confirming previous
reports (Zeng et al, 1983; Ji et al, 2003b), we demonstrated in a
large-scale study that this trend could be reversed using a
screening program that employed serological testing and clinical
examination. Here, 68% of the cases thus detected by the screening
program were diagnosed at the early stage I or II disease.
Nasopharyngeal carcinoma mainly affects adults in their most
productive age, between 35 and 65 years (Yu and Yuan, 2002). Our
findings suggest that effective control of this cancer can be
achieved by repeating serologic screening every 2 years to identify
cases as they enter the serologic window. We estimate that such a
program would sustain a prediction rate of 90% and more
importantly about two-third of these cases diagnosed by the
program belongs to early-stage disease. Apart from benefits to
the afflicted individuals, such a program, when implemented
community-wide in high-incidence areas for this cancer, would
have important economic and sociological ramifications. We
believe that we have shown this to be a practical proposition.
Moreover, the VCA IgA assay used in this study, the only suitable
assay at the time, has now been replaced by high-throughput
objective assays produced with purified recombinant EBV
proteins, which afford greater specificity and sensitivity than
Type +  −
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Time of diagnosis
(years after screening)
Figure 5 Preclinical serologic profiles and time of subsequent diagnosis
of NPC cases. One hundred and seven NPC cases were diagnosed 8
months to 15 years after enrollment; 56 cases were from seropositive
group (þ) and 51 from seronegative group ( ). Cases were separated
according to their preclinical serologic profiles into three categories,
designated types I, II and to III, as described in Figure 4. Whiskers, boxes and
lines in the diagram depict range, interquartile and median times of
diagnosis, respectively. Time of diagnosis of the three types of cases is
significantly different (w
2¼39.332, df¼2, Po0.0001).
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Figure 6 Cumulative detection of NPC cases of different preclinical EBV
serologic profiles. One hundred and seven NPC cases were separated into
three categories, designated types I–III, according to their preclinical
serologic profiles (see Figure 4): type I cases are indicated by closed
triangles, type II by open triangles and type III by open squares.
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straditional assays, especially when they are used in combination
(Cheng et al, 2002). Detection of the EBV gene in nasopharyngeal
swabs from symptomatic patients has been shown to be highly
predictive of symptomatic NPC (Hao et al, 2003; Tsang et al, 2003),
and the incorporation of this approach in routine NPC screening
of apparently healthy subjects is expected to enhance early
detection of the cancer.
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